Anúncio
Anúncio
VRDN
Viridian Therapeutics, Inc. Common Stock
30.68
USDPatrocinado
-0.44
-1.40%
02 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
31.00
+0.31
+1.01%
Relatórios de Lucros VRDN
Rácio de surpresa positiva
VRDN separação 22 de 38 últimas estimativas.
58%
Próximo Relatório
Data do Próximo Relatório
25 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$12.99M
/-$1.09
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-81.60%
/+220.59%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+17935.91%
/+9.00%
Viridian Therapeutics, Inc. Common Stock earnings per share and revenue
On 05 de nov. de 2025, VRDN reported earnings of -0.34 USD per share (EPS) for Q3 25, beating the estimate of -1.10 USD, resulting in a 69.21% surprise. Revenue reached 70.57 milhão, compared to an expected 34.59 mil, with a 203930.30% difference. The market reacted with a +8.29% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analistas forecast an EPS of -1.09 USD, with revenue projected to reach 12.99 milhão USD, implying an aumentar of 220.59% EPS, and diminuir of -81.60% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
19 de dez. de 2025 Para Q4 25
Estimativa
-$0.25
Real
-$0.19
Surpresa
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Viridian Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Viridian Therapeutics, Inc. Common Stock reported EPS of -$0.34, beating estimates by 69.21%, and revenue of $70.57M, 203930.3% above expectations.
How did the market react to Viridian Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 8.29%, changed from $22.55 before the earnings release to $24.42 the day after.
When is Viridian Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 25 de fev. de 2026.
What are the forecasts for Viridian Therapeutics, Inc. Common Stock's next earnings report?
Based on 17
analistas, Viridian Therapeutics, Inc. Common Stock is expected to report EPS of -$1.09 and revenue of $12.99M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio